Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors

REDWOOD CITY, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to its Board of Directors (“Board”) where he will serve as Chairman of the Audit Committee. Mr. Labrucherie is currently the Chief Operating Officer and Chief Financial Officer of Nektar Therapeutics.

Nevan Elam, Chairman and Chief Executive Officer, stated, “We are thrilled to welcome Gil to our Board. He is a seasoned, industry veteran with a broad range of experiences and we look forward to obtaining the benefit of his insight as we advance the Company and prepare to list on a national stock exchange.”

“I am delighted to join Rezolute’s Board at such a critical juncture, as the Company prepares to uplist and to advance its lead program, RZ358, into Phase 2b clinical studies,” said Mr. Labrucherie.

Mr. Labrucherie brings nearly 25 years of senior leadership experience in finance, legal and corporate development to the Board. Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a member of the State Bar of California and is a Certified Management Accountant.

About Rezolute, Inc.
Rezolute is a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting rare and metabolic diseases. Rezolute is advancing a diversified pipeline including: RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital Hyperinsulinism; RZ402 (PC), a plasma kallikrein inhibitor targeting Diabetic Macular Edema; and AB101 (Phase 1), a once-weekly injectable basal insulin. For more information, visit: www.rezolutebio.com.

Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

Contact:
Keith Vendola, M.D.
Chief Financial Officer
keith@rezolutebio.com
650-308-4657

Released November 25, 2019